Age Mean ±SD | 35.6±16.1 | 36.1±19.2 | 25.6±10.2 | 0.03* 0.043** |
Gender | | | | |
Male | 25 (29.8) | 11 (27.5) | 4 (17.4) | 0.497 |
Female | 59 (70.2) | 29 (72.5) | 19 (82.6) | |
Anti AChR antibody | | | | |
Positive | 80 (95.2) | 30 (75) | 20 (87) | 0.004 |
Anti-MuSK antibody | | | | |
Positive | 0 (0) | 8 (20) | 0 (0) | 0.000 |
Double seronegative | 4 (4.8) | 4 (10) | 3 (13) | |
NCS | | | | |
Decremental response | 33 (39.3) | 20 (50) | 12 (52.2) | 0.002 |
Normal | 11 (13.1) | 4 (10) | 9 (39.1) | |
Not done | 40 (47.6) | 16 (40) | 2 (8.7) | |
Treatment | | | | |
Pyridostigmine | 7 (8.3) | 2 (5) | 5 (21.7) | 0.000 |
Azathioprine | 0 (0) | 4 (10) | 0 (0) | |
Pyridostigmine, prednisolone, with or without azathioprine | 65 (77.4) | 18 (45) | 11 (47.8) | |
Pyridostigmine, prednisolone, with or without azathioprine, and one dose IVIg | 2 (2.4) | 8 (20) | 0 (0) | |
Pyridostigmine, prednisolone, and mycophenolate | 2 (2.4) | 6 (15) | 3 (13) | |
Pyridostigmine, prednisolone, with or without azathioprine, and monthly IVIg | 8 (9.5) | 2 (5) | 4 (17.4) | |
Thymectomy | | | | |
Done | 55 (65.5) | 18 (45) | 19 (82.6) | 0.009 |
Not done | 29 (34.5) | 22 (55) | 4 (17.4) | |
Treatment response | | | | |
Controlled | 59 (70.2) | 23 (57.5) | 19 (82.6) | 0.106 |
Not controlled | 25 (29.8) | 17 (42.5) | 4 (17.4) | |
CT chest | | | | |
Prominent thymus | 19 (22.6) | 11 (27.5) | 0 (0) | 0.003 |
Thymoma | 9 (10.7) | 8 (20) | 0 (0) | |
Normal | 56 (66.7) | 21 (52.5) | 23 (100) | |
Histopathology | | | | |
Thymic hyperplasia | 35 (41.7) | 13 (32.5) | 9 (39.1) | 0.000 |
Thymoma | 9 (10.7) | 4 (10) | 0 (0) | |
Normal | 11 (13.1) | 1 (2.5) | 10 (43.5) | |
Clinical state at the end of follow up | | | |
Ocular | 7 (8.3) | 0 (0) | 0 (0) | 0.003 |
Bulbar | 0 (0) | 4 (10) | 0 (0) | |
Generalized | 77 (91.7) | 36 (90) | 23 (100) | |
Serology | | | | |
Positive | 82 (97.6) | 38 (95) | 20 (87) | 0.104 |
Negative | 2 (2.4) | 2 (5) | 3 (13) | |